Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chugai’s DMD Gene Therapy Now in Line for Conditional Approval
April 21, 2025
- Lower House Passes Bill to Amend PMD Act
April 21, 2025
- MOF Tells LDP Members Govt Can Address Inflation with Current Budget Policy
April 21, 2025
- MHLW Panel to Discuss Approval of ASKA’s Contraceptive Pill and More on April 25
April 18, 2025
- Lower House Health Committee OKs Bill to Amend PMD Act, Adopts Supplementary Resolution
April 17, 2025
- MHLW Provides Draft Policymaking Document for Off-Year Revision after Opposition’s Call
April 17, 2025
- MHLW Looking into Impact of US Tariffs, Seeks Drug Makers’ Support
April 17, 2025
- MHLW to Revise Patent Linkage Scheme in FY2025, Create Expert Committee
April 16, 2025
- LDP’s Pharma Study Group Likely to Stay Even after Its Chair Bows Out
April 16, 2025
- PMD Act Bill Set for Lower House Committee Vote on April 16
April 16, 2025
- LDP Drug Innovation Project Team Eyes Inclusion of MCMs in Honebuto
April 15, 2025
- Chugai’s DMD Gene Therapy Up for Japan Panel Review on April 18
April 14, 2025
- MHLW Panel to Review Moderna’s RSV Jab, GSK’s ADC, and More on April 21
April 14, 2025
- Japan Govt Ends Subsidies for COVID Vaccinations from FY2025
April 14, 2025
- Scrap Coverage for OTC-Like Drugs with Same APIs and Dose as OTC Meds: Nippon Ishin
April 14, 2025
- Generic Dispensing Rates Spike on New LLP Coverage Rule: Survey
April 11, 2025
- 250 LDP Lawmakers Sign Petition for Revisiting Budget Cap, Off-Year Cuts
April 11, 2025
- MHLW on Alert for Potential Tariffs on Osteomalacia, Schizophrenia Meds
April 11, 2025
- Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
- Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
April 10, 2025
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…